Phase 3 N=1,128 MGR001 / Advair Diskus Local Equivalence Study in Asthma
Asthma
Primary: Forced Exhaled Volume in 1 Sec (FEV1) Area Under the Effect Curve on Day 1 (Assay Sensitivity) — 3.9534; 3.4964; 0.8191 L*hr — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=21 Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer
Neoplasms, Breast
Primary: Percentage of Participants With Tumor Response Measured by Breast MRI — 90.5 Percentage of participants
Phase 2 N=32 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients Completing the Protocol — 27 Participants
N/A N=381 Safety and Effectiveness of STSF Catheter Evaluated for Treating Symptomatic Persistent Atrial Fibrillation (PsAF)
Atrial Fibrillation
Primary: Primary Safety Endpoint - Percentage of Participants With Any PAE Within 7 Days — 4.7 Percentage of participants
N/A N=90 The Impact of IV Acetaminophen on Pain After Appendectomy for Perforated Appendicitis
Perforated Appendicitis
Primary: Time Until PCA Discontinued After the Operation — 76.4; 86.7 hours
Phase 3 N=1,846 A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
Breast Cancer
Primary: Invasive Disease-Free Survival (IDFS) in the Node-Positive Subpopulation — 94.10; 92.75 Percent Probability — p=0.8270
Phase 2 N=15 Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Myelodysplastic Syndrome
Primary: Incidence of Acute Graft Versus Host Disease (GVHD) Grade III/IV — 2; 2 participants
Phase 2 N=51 Autism Oxytocin Brain Project
Autism · Autism Spectrum Disorder
Primary: Resting State Functional Connectivity (rsFC) Salience Network (Anterior Cingulate Cortex (ACC) and Insula Versus Visual Cortex) — 0.338; 0.400; 0.428; 0.522 z-scores…
N/A N=24 Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.
Immunosuppression · Renal Failure
Primary: Renal Function as Measured by 24 Hour Urine Creatinine Clearance — 68.09; 70.75; 68.09; 86.8 mL/min
Phase 1 N=23 Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.
Paroxysmal Nocturnal Hemoglobinuria
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity — 2; 18; 2; 9 Participants
Phase 2 N=152 A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
Thyroid Cancer
Primary: Objective Response Rate (ORR) as of Week 24 (ORR24wk) — 57.3; 40.3 percentage of participants
Phase 3 N=270 Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
Ankylosing Spondylitis
Primary: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 16 — 56.39; 29.41 Percentage of participants…
Phase 2 N=53 Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy
Postoperative Pain · Inguinal Hernia
Primary: Total Use of Opioid Rescue Analgesia Over 0 to 24 Hours — 18.48; 24.60 mg
Phase 2 N=8 Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations
KRAS NP_004976.2:p.G12R · Stage III Pancreatic Cancer AJCC v6 and v7 · Stage IV Pancreatic Cancer AJCC v6 and v7
Primary: Proportion of Participants With an Objective Response (Partial Response + Complete Response) — 0; 0; 0; 0 Proportion of participants
Phase 2 N=34 A Confirmation Study of Eribulin in Combination With Capecitabine
Metastatic Breast Cancer
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI…